Pitch Engine

Times Advertising


.

Why Headless CMS Is Critical for Cross-Border Brand Consistency: Building One Global Voice Across Many Markets

The larger a brand grows, the easier it becomes to jeopardize consistent communications. Brand experiences are impacted across different languages, cultures, legalities and marketing strat...

Using Structured Content to Build Multi-Step Marketing Funnels: A Scalable Framework for Guided Conversion

Multi-step marketing funnels aim to take users from awareness to conversion and through subsequent stages. Where basic funnels capture all momentum on one landing page, modern marketing ef...

From Pages to Components: How Headless CMS Changes Content Strategy

For years, content strategy was all about pages. Websites were created, written, designed, and optimized one by one, with content closely connected to placement and presentation. It made s...

Supporting Real-Time Interfaces with API-First Content Systems

Real-time interfaces have changed user expectations across many digital solutions. From live data dashboards to conversational interfaces and collaborative platforms, in-app alerts and con...

Biosafety Cabinet vs Ductless Fume Hood: Engineering Safety in Modern Laboratories

Why Containment Equipment Defines Research Integrity The modern laboratory is an environment of controlled risks. Whether handling infectious microorganisms or volatile organic solvents, ...

How Small Businesses Can Compete With Big Brands In Media Coverage?

Corporations with massive marketing expenditures are no longer the sole beneficiaries of media exposure in the contemporary digital era. Small businesses now have access to tools, platforms...

新加坡 - Media OutReach Newswire - 2024年8月28日 - 亚洲领先医疗解决方案公司裕利医药（Zuellig Pharma）宣布和再生元制药（Regeneron Pharmaceuticals, Inc.）的全资子公司Regeneron Ireland DAC达成独家分销协议，将在韩国和台湾市场推出以T细胞免疫检查点受体为靶标的全人源化单抗Libtayo®（西米普利单抗）并助其商业化。 再生元制药是亚洲领先的生物科技企业，专注于发明、开发、商业化改变生命的重疾药物。Libtayo®（西米普利单抗）目前已在韩国获批为针对晚期非小细胞肺癌（NSCLC）的一线单药治疗方案，以及针对转移或局部晚期皮肤鳞状细胞癌（CSCC）和复发或转移性宫颈癌的药物，在台湾地区亦获得针对晚期非小细胞肺癌一线单药治疗方案的批准。 "我们很高兴加快将Libtayo® 提供给韩国和台湾市场患者的进程。凭借过往业绩以及对亚洲复杂生物制药环境的深入理解，我们在向上述区域患者提供创新治疗药物方面具备独特优势。这代表我们在实现'让医疗服务更普及，改善患者预后，尤其是在迅速发展的癌症治疗领域'的愿景上达成了重要里程碑。"裕利医药CEO John Graham表示。 Libtayo®利用再生元制药的专有VelocImmune®技术开发，目前已在超过二十四个国家获准用于治疗各种适应症。 Hashtag: #ZuelligPharma #Regeneron #Oncology #Libtayo #Biotechnology #Healthcare #Pharmaceuticals

发布方对本公告的内容负全部责任。

关于裕利医药（Zuellig Pharma）

裕利医药是亚洲最大的医疗健康服务供应商之一，以「让医疗服务更普及」为愿景。我们提供国际顶尖的分销、数字化和商业服务，以支持该地区日益增长的医疗需求。裕利医药自创立一百多年以来，已发展成市值数百亿美元的企业，覆盖16个市场，拥有12,000多名员工。我们的员工为超过20万家医疗机构提供服务，合作客户超过450家，其中不乏全球排名前20名的国际制药公司。 ZP Therapeutics，是裕利医药旗下的业务部门之一，是医疗健康行业值得信赖的商业化合作伙伴，在亚洲 13 个地区设有办事处，拥有超过 2,500 多名员工。 ZP Therapeutics 通过卓越的商业水准、高超的市场能力和严格的道德操守，成为改善患者体验和医疗健康成果的催化剂，是扩大患者供给渠道为医疗健康界提供创新的值得信赖的合作伙伴 。 欲了解更多资讯，请访问:

Source https://www.media-outreach.com/news/singapore/2024/08/28/320546/